Cost-effectiveness of point-of-care C-reactive protein testing to inform antibiotic prescribing decisions

British Journal of General Practice

Volumn 63, Issue 612, 2013, Pages

  Oppong, Raymond ^a   Jit, Mark ^b   Smith, Richard D ^c   Butler, Christopher C ^d   Melbye, Hasse ^e   Mölstad, Sigvard ^f   Coast, Joanna ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF TROMSØ   (Norway)

^f LUND UNIVERSITY   (Sweden)

Author keywords

Antibiotics; C reactive protein; Cost effectiveness; Primary health care; Respiratory tract infections

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUGHING; DIAGNOSTIC TEST; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NORWAY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POINT OF CARE TESTING; PRIMARY MEDICAL CARE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; SWEDEN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ATTITUDE OF HEALTH PERSONNEL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COST-BENEFIT ANALYSIS; DECISION MAKING; FEMALE; HUMANS; MALE; MIDDLE AGED; NORWAY; PHYSICIAN'S PRACTICE PATTERNS; POINT-OF-CARE SYSTEMS; PRIMARY HEALTH CARE; QUESTIONNAIRES; RESPIRATORY TRACT INFECTIONS; SWEDEN;

EID: 84880530477     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp13X669185     Document Type: Article

References (32)

1. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 278(17): 1440-1445.
2. van der Meer V, Neven AK, Van den Broek PJ, Assendelft WJJ. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ 2005; 331(7507): 26.
3. Graffelman AW, Le Cessie S, Knuistingh NA, et al. Can history and exam alone reliably predict pneumonia? J Fam Pract 2007; 56(6): 465-470.
4. Cals JWL, Hopstaken RM, Butler CC, et al. Improving management of patients with acute cough by C-reactive protein point of care testing and communication training (IMPAC 3 T): study protocol of a cluster randomised controlled trial. BMC Fam Pract 2007; 8: 15.
5. Ip M, Rainer TH, Lee N, et al. Value of serum procalcitonin, neopterin, and C-reactive protein in differentiating bacterial from viral etiologies in patients presenting with lower respiratory tract infections. Diagn Microbiol Infect Dis 2007; 59(2): 131-136.
6. Cals JWL, Butler CC, Hopstaken RM, et al. Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. BMJ 2009; 338: b1374.
7. Jakobsen KA, Melby H, Kelly MJ, et al. Influence of CRP testing and chest findings on antibiotic prescribing in adults presenting with acute cough in primary care. Scand J Prim Health Care 2010; 28(4): 229-236.
8. Hansson LO, Carlsson I, Hansson E, et al. Measurement of C-reactive protein and the erythrocyte sedimentation rate in general practice. Scand J Prim Health Care 1995; 13(1): 39-45.
9. Dahler-Eriksen BS, Lauritzen T, Lassen JF, et al. Near-patient test for C-reactive protein in general practice: assessment of clinical, organizational, and economic outcomes. Clin Chem 1999; 45(4): 478-485.
10. Flanders SA, Stein J, Shochat G, et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am J Med 2004; 116(8): 529-535.
11. Weis N, Almdal T. C-reactive protein - can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease? Eur J Intern Med 2006; 17(2): 88-91.
12. Galetto-Lacour A, Zamora SA, Gervaix A. Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center. Pediatrics 2003; 112(5): 1054-1060.
13. Kohli V, Singhi S, Sharma P, Ganguly NK. Ann Trop Paediatr 1993; 13(4): 373-378.
14. Diederichsen HZ, Skamling M, Diederichsen A, et al. Randomised controlled trial of CRP rapid test as a guide to treatment of respiratory infections in general practice. Scand J Prim Health Care 2000; 18(1): 39-43.
15. Butler CC, Hood K, Verheij T, et al. Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries. BMJ 2009; 338: b2242.
16. Oppong R, Coast J, Hood K, et al. Resource use and costs of treating acute cough/lower respiratory tract infections in 13 European countries: results and challenges. Eur J Health Econ 2011; 12(4): 319-329.
17. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd edn. Oxford: Oxford University Press, 2005.
18. Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states. Eur J Health Econ 2003; 4(3): 222-231.
19. Watson L, Little P, Moore M, et al. Validation study of a diary for use in acute lower respiratory tract infection. Fam Pract 2001; 18(5): 553-554.
20. Rawlings M, Barnett D, Stevens A. Pharmacoeconomics: NICE's approach to decision-making. Br J Clin Pharmacol 2010; 70(3): 346-349.
21. Hoch JS, Rockx MA, Krahn AD. Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of 'community acquired' syncope. BMC Health Serv Res 2006; 6: 68.
22. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness and cost-effectiveness analysis. Health Econ 2002; 11(5): 415-430.
23. Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Econ 2001; 10(2): 179-184.
24. McKee M, Britton A, Black N, et al. Methods in health services research: interpreting the evidence: choosing between randomised and non-randomised studies. BMJ 1999; 319(7205): 312-315.
25. Cals JW, Ament AJ, Hood K, et al. C-reactive protein point of care testing and physician communication skills training for lower respiratory tract infections in general practice: economic evaluation of a cluster randomized trial. J Eval Clin Pract 2011; 17(6): 1059-1069.
26. Coast J, Smith RD, Millar MR. Superbugs: should antimicrobial resistance be included as a cost in economic evaluation? Health Econ 1996; 5(3): 217-226.
27. Coast J, Smith RD. Solving the problem of antimicrobial resistance: is a global approach necessary? Drug Discov Today 2003; 8(1): 1-2.
28. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363(9409): 600-607.
29. Ball P, Baquero F, Cars O, et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002; 49(1): 31-40.
30. Goossens H, Guillemot D, Ferech M, et al. National campaigns to improve antibiotic use. Eur J Clin Pharmacol 2006; 62(5): 373-379.
31. Voss A, Milatovic D, Wallrauch-Schwarz C, et al. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994; 13(1): 50-55.
32. Laxminarayan R, Brown GM. Economics of antibiotic resistance: a theory of optimal use. J Environ Econ Manage 2001; 42(2): 183-206. Antibiotics in Community-Acquired LRTI in Europe